Babies born between 33 and 35 weeks of gestation who were given palivizumab within their first six months of life were less likely to develop recurrent wheezing during their first three years than those who did not get the medication, a Japanese study in the journal Pediatrics showed. Of the 349 babies in the palivizumab group, 6.4% had repeated wheezing compared to nearly 19% in the control group.

Full Story:

Related Summaries